Renal & Metabolic

George Clinical has established a reputation as the clinical research organization of choice for conduct of renal trials.

Renal & Metabolic

George Clinical’s scientific expertise is derived from leading researchers with a track record in developing new strategies for the treatment and prevention of kidney disease across diverse populations. George Clinical leverages this expertise and prominence in the renal field to design effective studies and accelerate recruitment. George Clinical aims to make an impact with all its trials and as such generates strong clinical evidence for new therapies and devices.

George Clinical’s scientific expertise is derived from researchers with a leading track record of developing new strategies for the prevention and treatment of kidney diseases, for example by targeting their key risk factors such as blood pressure and diabetes. They also focus on improving outcomes for people with established kidney disease, such as those requiring dialysis. George Clinical leverages this in-depth knowledge and prominence in the renal field to design effective studies and accelerate recruitment.

George Clinical aims to make an impact with all its trials and as such generates strong clinical evidence for new therapies and devices.

Some of George Clinical’s success in renal studies include:

  • Major trials in diabetes, including ADVANCE, CANVAS, SONAR and CREDENCE, have collectively recruited tens of thousands of people with diabetes and/or kidney disease and reliably defined the effects of a range or major treatments.
  • The largest trial ever conducted in severe acute renal failure recruited 1,508 participants in 35 intensive care units. The study demonstrated similar outcomes for standard and intensive dialysis on 90-day mortality.
  • A trial randomizing participants with end-stage kidney failure to either standard dialysis or extended hour dialysis, assessed the impact on quality of life and other important clinical outcomes.
  • A large-scale trial, recruiting 8,600 patients, developed in partnership with the Veterans Administration (USA) provided definitive evidence for the effects of two commonly used agents upon the risk of patient harm following angiographic procedures.
  • The ongoing 45 And Up Study, a large-scale cohort study, has recruited more than 250,000 New South Wales (Australia) residents aged 45 years and older (representing 10% of the population in that age bracket). The study examines the complete disease pathway for people with diabetes and Chronic Kidney Disease (CKD).
  • A number of multi-country trials with global pharmaceutical companies investigate renal outcomes in diabetic kidney disease.
  • The SHARP study evaluated whether lowering cholesterol in patients with kidney disease affected their risk of having a heart attack, stroke or death. The study involved more than 9,000 patients with lower than normal kidney function (chronic kidney disease) in 380 hospitals across 18 countries.

Our clinical trial services in renal health include:

Our renal site network is one of the strongest in the world, and especially in Asia.

 

Webinars:

Challenges in Adjudicating Endpoints for Kidney Disease

Renal Trials in Asia-Pacific: Opportunities and Advancements

 

CREDENCE Trial

A breakthrough treatment for kidney disease and diabetes

George Clinical's Renal & Metabolic Scientific Leadership

Hiddo Lambers Heerspink is affiliated with the Department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen, the Netherlands. He received his PhD from the medical faculty of the University Medical Center Groningen in 2008. He then worked as a post-doctoral fellow at The George Institute in Sydney, Australia where he investigated the effects of blood pressure lowering regimens on renal and cardiovascular outcomes in patients with renal impairment. Based on this work, he was awarded a young investigator grant and, subsequently in 2015, a consolidator investigator grant from the Dutch organization of scientific research.

Since 2010, Professor Heerspink has held a position as a Clinical Pharmacologist at the University Medical Center Groningen. He is currently Professor Clinical Trials and Personalized Medicine. His main research interests include optimizing treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. His clinical research interest is to identify determinants of individual treatment responses and ways to optimize drug response in individual patients. To achieve these goals, he is involved in various international clinical trials and uses biomarkers and imaging techniques to unravel pathways and determinants of therapy response.

Martin holds positions as Associate Professor, Faculty of Medicine, UNSW Sydney, Associate Professor of Medicine at Concord Hospital Clinical School (part of the Sydney Medical School), Director of the Renal and Metabolic Division in the George Institute and a clinical nephrologist in the Renal Dept. at Concord Repatriation and General Hospital. He works extensively in the ANZ Society of Nephrology in renal guidelines and clinical policy.

Martin’s research interests include large scale clinical trials to explore ways to improve the outcomes of patients with kidney disease (esp. in the setting of acute kidney injury), extending the follow up of such clinical trials to understand the long-term effects of treatments, measurement of health systems and the means of applying research evidence into practice.

 

 

Dr. Adrian Liew is a Senior Consultant Nephrologist and Director of The Kidney and Transplant Practice at Mount Elizabeth Novena Hospital in Singapore. He was the founding Chief of Nephrology at the Department of Renal Medicine in Tan Tock Seng Hospital, Singapore, and was an Associate Professor of Medicine, in charge of the Renal Medicine Curriculum and Clinical OSCEs, with the LKC School of Medicine at the Imperial College London-Nanyang Technological University before moving to his current role.

He is a member of the Executive Committee and elected council member of the International Society of Nephrology (ISN) and chairs the ISN Oceania-Southeast Asia Regional Board and the ISN Renal Disaster Preparedness Working Group. He is also the elected secretary and executive of the International Society for Peritoneal Dialysis and is appointed a member of the KDIGO Guideline working groups for glomerular diseases as well as diabetic kidney disease. His research interests are in glomerular diseases, peritoneal dialysis and diabetic kidney diseases, and is the national leader and steering committee member for various multi-centre clinical trials.

Dr. Wong is Renal Physician at the Royal North Shore hospital, Sydney, Australia. He is also a senior research fellow at the George Institute of Global Health and holds a Senior Lecturer position, Faculty of Medicine, UNSW Sydney. His PhD entitled “Novel therapeutic options in models of nephropathy” was awarded in 2011.

His main area of research is in understanding the pathomechanisms of kidney tubulointerstitial fibrosis and biomarkers in predicting progression of chronic kidney disease particularly in diabetic kidney disease.
Dr. Wong has worked on kidney injury molecule-1, transforming growth factor-β1, bone morphogenetic protein-7, Farnesoid X receptor and novel anti-fibrotic and anti-inflammatory agents in extracellular matrix deposition in human proximal tubular cells and in vivo model of fibrosis.

His is also passionate in translation medicine and is involved in the post hoc analyses of the IDEAL study and currently involved in multicentre international trials at the George Institute including TESTING and SONAR study.

https://scholar.google.com/scholar?hl=en&as_sdt=0%2C43&q=muh+geot+wong&btnG=

Professor Vivekanand Jha is the Executive Director, The George Institute for Global Health, India, and James Martin Fellow at The George Institute for Global Health at the University of Oxford.

Prior to joining The George Institute, he was Professor of Nephrology and Head, Department of Translational Regenerative Medicine and Officer-In-Charge, Medical Education and Research Cell at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. Vivek serves on the international advisory boards of several organizations, including membership of the WHO Expert Advisory Panel on Human Cell, Tissue and Organ Transplantation, and the executive committee of the International Society of Nephrology.

He is on the EMJ Editorial Board, counselor of the International Society of Nephrology, a member of the education committees for the International Transplantation Society and International Society of Peritoneal Dialysis. He is a physician with a specialization in the area of kidney diseases and he focuses on emerging public health threats globally and in India. He is particularly interested in using multi-disciplinary approaches and innovation to address the major challenge posed to humanity by non-communicable diseases.

 

 

A/Prof Meg Jardine is a clinician researcher developing a program of research exploring the cardiovascular and other complications of chronic kidney disease and diabetes.

Dr. Jardine has worked as a Nephrologist in both the public and private sectors, where she directly manages chronic kidney disease and diabetes and their consequences for patients.

She is currently Deputy Director of the Renal & Metabolic Division at the George Institute for Global Health; Associate Professor at the Faculty of Medicine, UNSW Sydney; and holds an NHMRC Career Development Fellowship. She has presented her work in late breaking and prize sessions of the World Congress of Nephrology and the Australasian Nephrology conference and has published in high impact journals. Dr. Jardine is collaborating on the development and delivery of other national and international trials investigating methods to mitigate the excess burden of cardiovascular disease and is Chair of the Australasian Kidney Trials Network Haemodialysis Working Group.

 

 

Vlado Perkovic, MBBS, PhD, FRACP, FASN

  • Board Member, George Clinical
  • Dean of Medicine & Scientia Professor, UNSW

Vlado Perkovic is Dean of Medicine and Scientia Professor at UNSW, a Professorial Fellow at The George Institute, Australia, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He leads several major international clinical trials, and serves on the Steering Committees of several others. He has been involved in developing Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management.

Vlado holds a Doctor of Philosophy from the University of Melbourne and completed his undergraduate training at The Royal Melbourne Hospital. He is Chair of the International Society of Nephrology Action for Clinical Trials (ISN-ACT) group; and is a Fellow of the Royal Australasian College of Physicians, of the Australian Academy of Health and Medical Sciences and of the American Society of Nephrology

 

 

David is Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics and sodium glucose cotransporter 2 inhibitors in patients chronic kidney disease. He has developed clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. He is Past President of the UK Renal Association, past chair of the UK Renal Registry and currently National Institute for Health Research (NIHR) National Specialty Lead for Nephrology.

Roberto Pecoits-Filho, MD, PhD, FACP, FASN

  • Professor of Nephrology at the School of Medicine, Catholic University of Paraná State in Brazil, Senior Research Scientist, Arbor Research Collaborative for Health in the USA

Dr. Roberto Pecoits-Filho is currently a Senior Research Scientist, Arbor Research Collaborative for Health in the USA and a full professor at the School of Medicine, Catholic University of Paraná, where he was the director of the PhD and Masters Programs in Health Sciences, Chief of Nephrology and co-founder of the Academic Clinical Research Organization (ACRO) EPICENTER (Center of Epidemiology and Clinical Research) and PUCTrials in the same institution. Dr. Pecoits-Filho received his M.D. degree in 1993, trained in Internal Medicine and Nephrology in Curitiba and completed his nephrology fellowship at the University of Missouri, Columbia in 1997-98. He received a Ph.D. from the University of São Paulo and thereafter went to Sweden as a visiting scholar at the Karolinska Institutet from 1999 to 2002. Dr. Pecoits-Filho was a visiting fellow at the George Institute in Sydney in 2017.

Dr. Pecoits-Filho has been involved in clinical research since 2003, and was a principal investigator of 17 multicentric clinical trials. He is a National Leader of several ongoing clinical trials such as Credence, Olympus, and CKD DAPA and sits at the steering committee of the observational studies CKDOPPS, MONDO and BRAZPD. He was the Chair of the Steering Committee of the STARCH, SALTED and HDFit multicentric trials in Brazil that were coordinated by the ACRO PUCTrials. In those trials, he played an active role in study design, implementation, coordination, event adjudication, data management and led the data monitoring safety board (DMSB) for STARCH and HDFit.

Dr. Pecoits-Filho is part of the Editorial Board of American Journal of Kidney Diseases, Peritoneal Dialysis International, and Blood Purification. During his career, he has published his research in over 240 papers in international indexed journals, and lectured in more than 40 countries around the world.

In the past he was scientific director of the Brazilian Society of Nephrology and vice president of the Latin American Society of Nephrology and Hypertension. He was awarded the Young Nephrology Leader Award of the Global Kidney Academy, the Maher Award of the ISPD, Paraná State Award for Science and Technology and was an Education Ambassador of the ISN. Currently, he is a Councilor of the International Society of Nephrology. He is also a member of the Executive Committee of KDIGO and part of the Core Group of ISN’s Advancing Clinical Trials (ACT) Initiative, and the International Network of Chronic Kidney Disease Cohort Studies (iNET-CKD).

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network